Oral IIa Inhibitors

Mar 1, 2017 by in HEMATOLOGY Comments Off on Oral IIa Inhibitors

Direct oral factor IIa inhibitors represent a new class of anticoagulants for the prevention and treatment of venous and selected arterial thomboembolisms. Dabigatran etexilate is the most studied and promising…

read more

Oral Xa Inhibitors

Mar 1, 2017 by in HEMATOLOGY Comments Off on Oral Xa Inhibitors

Several new oral drugs that selectively and directly inhibit factor Xa seem promising alternatives to existing antithrombotic drugs. These drugs have a convenient route of administration, can be given in…

read more

Optimizing Use of Current Anticoagulants

Mar 1, 2017 by in HEMATOLOGY Comments Off on Optimizing Use of Current Anticoagulants

Although warfarin has been the mainstay of oral anticoagulation therapy for decades, evidence-based methods for improving the quality of warfarin therapy remain underused. The arrival of new anticoagulants that do…

read more

Cancer-Associated Thrombosis

Mar 1, 2017 by in HEMATOLOGY Comments Off on Cancer-Associated Thrombosis

Venous thromboembolic events are common in patients with malignancy, producing both morbidity and mortality. Although the underlying mechanisms by which cancer might promote a procoagulant state are multifaceted and incompletely…

read more

Novel Risk Factors for Venous Thromboembolism

Mar 1, 2017 by in HEMATOLOGY Comments Off on Novel Risk Factors for Venous Thromboembolism

VTE can be considered as a multicausal disease involving various inherited and acquired prothrombotic conditions. Although greater emphasis has classically been given to traditional thrombophilic risk factors, there is increasing…

read more
Get Clinical Tree app for offline access